[go: up one dir, main page]

MX2010006379A - Moduladores de la secretasa gamma. - Google Patents

Moduladores de la secretasa gamma.

Info

Publication number
MX2010006379A
MX2010006379A MX2010006379A MX2010006379A MX2010006379A MX 2010006379 A MX2010006379 A MX 2010006379A MX 2010006379 A MX2010006379 A MX 2010006379A MX 2010006379 A MX2010006379 A MX 2010006379A MX 2010006379 A MX2010006379 A MX 2010006379A
Authority
MX
Mexico
Prior art keywords
gamma secretase
secretase modulators
compounds
formula
modulators
Prior art date
Application number
MX2010006379A
Other languages
English (en)
Inventor
Xianhai Huang
Anandan Palani
Robert G Aslanian
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010006379A publication Critical patent/MX2010006379A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención provee compuestos novedosos que son moduladores de gamma secretasa; los compuestos tienen la fórmula (I) (ver fórmula I) se exponen también métodos de modular la actividad de gamma secretasa y métodos de tratar la enfermedad de Alzheimer usando los compuestos de la fórmula (1).
MX2010006379A 2007-12-11 2008-12-09 Moduladores de la secretasa gamma. MX2010006379A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1286307P 2007-12-11 2007-12-11
PCT/US2008/086030 WO2009076337A1 (en) 2007-12-11 2008-12-09 Gamma secretase modulators

Publications (1)

Publication Number Publication Date
MX2010006379A true MX2010006379A (es) 2010-09-07

Family

ID=40409932

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006379A MX2010006379A (es) 2007-12-11 2008-12-09 Moduladores de la secretasa gamma.

Country Status (7)

Country Link
US (1) US20100298372A1 (es)
EP (1) EP2268636A1 (es)
JP (1) JP2011506460A (es)
CN (1) CN101970433A (es)
CA (1) CA2708151A1 (es)
MX (1) MX2010006379A (es)
WO (1) WO2009076337A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2257541B1 (en) 2008-02-22 2013-08-14 F. Hoffmann-La Roche AG Modulators for amyloid beta
MX2011003246A (es) 2008-10-09 2011-04-21 Hoffmann La Roche Moduladores de beta amiloide.
EP2367826A4 (en) 2008-11-06 2012-07-04 Astrazeneca Ab MODULATORS OF THE PROTEIN -AMYLOID
WO2010052199A1 (en) 2008-11-10 2010-05-14 F. Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
SG176628A1 (en) 2009-06-05 2012-01-30 Link Medicine Corp Aminopyrrolidinone derivatives and uses thereof
WO2011007819A1 (ja) 2009-07-17 2011-01-20 塩野義製薬株式会社 ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬
TWI468402B (zh) * 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
US20110190269A1 (en) * 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
ES2602794T3 (es) 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
TW201247631A (en) 2011-04-28 2012-12-01 Du Pont Herbicidal pyrazinones
EP3290413B9 (en) 2011-12-21 2020-04-29 ONO Pharmaceutical Co., Ltd. Pyridinone and pyrimidinone derivatives as factor xia inhibitors
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
CN105555767B (zh) * 2013-07-23 2018-03-23 拜耳制药股份公司 取代的氧代吡啶衍生物及其作为因子xia/血浆的用途
ES2927307T3 (es) 2014-12-10 2022-11-04 Ono Pharmaceutical Co Derivado de dihidroindolizinona
BR112017015693A2 (pt) 2015-02-03 2018-03-20 Pfizer ciclopropabenzofuranil piridopirazinadionas
EP3481829B1 (en) 2016-07-08 2021-04-07 H. Hoffnabb-La Roche Ag Fused pyrimidine derivatives
EP3523304B1 (en) 2016-10-04 2021-01-27 H. Hoffnabb-La Roche Ag Bicyclic heteroaryl derivatives
EP3632906B1 (en) * 2017-05-24 2023-12-13 Abbisko Therapeutics Co., Ltd. Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy
JP6903825B2 (ja) * 2017-12-19 2021-07-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング γ−セクレターゼのモジュレーターとしてのトリアゾロピリジン
CN112028877B (zh) * 2019-06-04 2021-11-26 江西济民可信集团有限公司 烷氧吡啶酮化合物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869500A (en) * 1996-12-13 1999-02-09 Hoffmann-La Roche Inc. Pyridone compounds useful in treating Alzheimer's disease
AU2002365132A1 (en) * 2001-10-17 2003-07-15 Bristol-Myers Squibb Company BICYCLIC LACTAM DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-Alpha CONVERTING ENZYME (TACE)
AU2004311577A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
MY149038A (en) * 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
US20070117839A1 (en) * 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
EP1953154A4 (en) * 2005-11-24 2013-11-20 Eisai R&D Man Co Ltd CINNAMIDE COMPOUNDS OF MORPHOLINE TYPE
KR101464651B1 (ko) * 2006-03-09 2014-11-24 에자이 알앤드디 매니지먼트 가부시키가이샤 다환식 신나미드 유도체

Also Published As

Publication number Publication date
WO2009076337A1 (en) 2009-06-18
JP2011506460A (ja) 2011-03-03
CA2708151A1 (en) 2009-06-18
US20100298372A1 (en) 2010-11-25
EP2268636A1 (en) 2011-01-05
CN101970433A (zh) 2011-02-09

Similar Documents

Publication Publication Date Title
MX2010002674A (es) Moduladores de gamma secretasa.
MX2010006379A (es) Moduladores de la secretasa gamma.
MX2010005028A (es) Moduladores de gamma secretasa.
MX2010006378A (es) Moduladores de gamma secretasa.
MX2010006046A (es) Moduladores de gamma secretasa.
MX2010006243A (es) Moduladores de gamma secretasa.
WO2005113542A3 (en) N-cyclic sulfonamido inhibitors of gamma secretase
MX2009012177A (es) Moduladores de gamma-secretasa.
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
MX2010002712A (es) Compuestos que modulan calcio intracelular.
SG10201811480WA (en) Therapeutic compounds and compositions
IN2012DN00869A (es)
MX2009013131A (es) Moduladores de gamma secretasa.
TN2009000291A1 (en) Inhibitors of mek
MY157445A (en) Compounds that modulate intracellular calcium.
MX2007011859A (es) Compuestos mejorados farmacocineticamente.
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
TW200626068A (en) Active compounds for seed treatment
NO20076413L (no) Multisykliske forbindelser og fremgangsmater for deres anvendelse
TW200738666A (en) Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
GB2466912A (en) Compositions and methods for treating lysosomal disorders
MX2009003981A (es) Agentes moduladores del receptor de calcio.
WO2010075280A3 (en) Coumarin-based compounds for the treatment of alzheimer's disease and cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal